Memokath-051 stent for ureteric obstruction: draft guidance
We are listening to your views on this Medical technologies guidance. Comments close 13 September 2022.
Search results
218 results
-
-
KardiaMobile 6L for measuring cardiac QT interval in people having antipsychotic medication: diagnostics consultation
We are listening to your views on this Diagnostics guidance. Comments close 25 August 2022.
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin's lymphoma [ID1685]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 31 August 2022.
-
Kurin Lock for Blood Collection
Awaiting development [GID-MT582] Expected publication date: TBC
-
TriageHF Plus
Awaiting development [GID-DG10064] Expected publication date: TBC
-
Sintilimab with pemetrexed and platinum-based chemotherapy for untreated advanced non-squamous non-small-cell lung cancer [ID4050]
Awaiting development [GID-TA10934] Expected publication date: TBC
-
Fordadistrogene movaparvovec for the treatment of Duchenne muscular dystrophy TS ID 10420
Awaiting development [GID-TA11044] Expected publication date: TBC
-
Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer TS ID 10759
Awaiting development [GID-TA11021] Expected publication date: TBC
-
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757
Awaiting development [GID-TA11019] Expected publication date: TBC
-
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]
Awaiting development [GID-TA11033] Expected publication date: TBC
-
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947
Awaiting development [GID-TA10834] Expected publication date: TBC
-
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765
Awaiting development [GID-TA11050] Expected publication date: TBC
-
Bimekizumab for treating moderate to severe hidradenitis suppurativa TS ID 10637
Awaiting development [GID-TA11045] Expected publication date: TBC
-
Leniolisib for untreated activated phosphoinositide 3-kinase delta syndrome in people 12 years and over TS ID 10657
Awaiting development [GID-TA11046] Expected publication date: TBC
-
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683
Awaiting development [GID-TA11053] Expected publication date: TBC
-
Selpercatinib for untreated RET-positive advanced medullary thyroid cancer in people 12 years and over TS ID 10762
Awaiting development [GID-TA11047] Expected publication date: TBC
-
Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy TS ID 10763
Awaiting development [GID-TA11048] Expected publication date: TBC
-
Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy TS ID 10764
Awaiting development [GID-TA11049] Expected publication date: TBC
-
Cedazuridine–decitabine for untreated acute myeloid leukaemia unsuitable for intensive chemotherapy TS ID 10605
Awaiting development [GID-TA11051] Expected publication date: TBC
-
REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443
Awaiting development [GID-TA11052] Expected publication date: TBC
-
Empagliflozin for treating chronic kidney disease TS ID 10698
Awaiting development [GID-TA11043] Expected publication date: TBC
-
Pegvaliase for treating phenylketonuria [ID1110]
Awaiting development [GID-TA10345] Expected publication date: TBC
-
Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]
Awaiting development [GID-TA10605] Expected publication date: TBC
-
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]
Awaiting development [GID-TA10700] Expected publication date: TBC
-
Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]
Awaiting development [GID-TA10774] Expected publication date: TBC
-
Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]
Awaiting development [GID-TA10776] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Awaiting development [GID-TA10604] Expected publication date: TBC
-
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]
Awaiting development [GID-TA10638] Expected publication date: TBC
-
Remimazolam for general anaesthesia [ID3796]
Awaiting development [GID-TA10679] Expected publication date: TBC
-
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Awaiting development [GID-TA10682] Expected publication date: TBC
-
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Awaiting development [GID-TA10684] Expected publication date: TBC
-
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]
Awaiting development [GID-TA10685] Expected publication date: TBC
-
Gosuranemab for treating progressive supranuclear palsy [ID1607]
Awaiting development [GID-TA10553] Expected publication date: TBC
-
Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]
Awaiting development [GID-TA10783] Expected publication date: TBC
-
Timrepigene emparvovec for treating choroideremia [ID3916]
Awaiting development [GID-TA10787] Expected publication date: TBC
-
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]
Awaiting development [GID-TA10791] Expected publication date: TBC
-
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]
Awaiting development [GID-TA10797] Expected publication date: TBC
-
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]
Awaiting development [GID-TA10800] Expected publication date: TBC
-
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]
Awaiting development [GID-TA10811] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]
Awaiting development [GID-TA10813] Expected publication date: TBC
-
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]
Awaiting development [GID-TA10823] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Awaiting development [GID-TA10826] Expected publication date: TBC
-
Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]
Awaiting development [GID-TA10722] Expected publication date: TBC
-
Benralizumab for previously treated severe nasal polyps [ID1659]
Awaiting development [GID-TA10818] Expected publication date: TBC
-
Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]
Awaiting development [GID-TA10662] Expected publication date: TBC
-
Sotagliflozin for treating type 2 diabetes [ID1657]
Awaiting development [GID-TA10665] Expected publication date: TBC
-
Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]
Awaiting development [GID-TA10694] Expected publication date: TBC
-
Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Awaiting development [GID-TA10574] Expected publication date: TBC
-
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]
Awaiting development [GID-TA10715] Expected publication date: TBC